Eurofins Scientific Sells Its MET Labs Division for 575 Million Euros
Eurofins Scientific has announced the signing of an agreement to sell its Electrical & Electronic Testing division (MET Labs) to UL Solutions Inc. for an enterprise value of 575 million euros. This transaction is part of the group's strategy to refocus on its life testing capabilities.
MET Labs is an international network of laboratories offering product safety testing, inspection, and certification services for electrical and electronic products. The division serves clients in consumer electronics, automotive, telecommunications, and industrial sectors, ensuring compliance with international safety and performance standards. MET Labs is expected to generate over 180 million euros in revenue by 2026, with profitability generally in line with the group's average, and employs approximately 1,300 staff worldwide.
Use of Sale Proceeds
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Eurofins states that the proceeds from this sale will fuel the group's capital allocation priorities, including debt reduction, investment in owned laboratories and sites, next-generation digital solutions, developments in robotics and artificial intelligence, share buybacks, and strategic acquisitions aimed at strengthening the group's market positions in the fields of food, environmental, pharmaceutical, clinical, and related testing.
Transaction Completion
The completion of the transaction remains subject to customary regulatory approvals and is expected to occur by the end of the year 2026.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
